4D Pharma

4D Pharma understands that the bacteria of the gut microbiome have an important function in health and disease, but importantly – we understand how they function, and how they could be used as potential new therapies.

Industries

Pharmaceutical

Headquarters

Aberdeen, United Kingdom

Stage

Post IPO Debt

Employees

51-200

Links

Org chart

Duncan Peyton

Chief Executive Officer

Collapse

Alex Stevenson

Chief Scientific Officer

John Doyle

Chief Financial Officer

Adrian Murray

General Counsel

Lucy Christie

Vice President of Human Resources

Teams

View all

Leadership Team

5 members

Board of Directors

5 members

CEO and Executive Team

3 members

Discover similar companies

Biofrontera

Heidelberg, Germany · Post IPO Equity

Sumo Group

Sheffield, United Kingdom · Post IPO Equity

Redx Pharma

England, United Kingdom · Grant

Vivesto

Uppsala, Sweden · Post IPO Equity

DURECT

Cupertino, United States · Post IPO Equity

Insys Therapeutics

Phoenix, United States · Post IPO Equity

Spectrum Pharmaceuticals

Henderson, United States · Post IPO Debt

Allergy Therapeutics

England, United Kingdom · Post IPO Equity

Arqit

London, United Kingdom · Post IPO Equity

Immatics

Tübingen, Germany · Post IPO Equity

Inspiration Healthcare

Leicester, United Kingdom · Post IPO Equity

Catalyst Pharmaceuticals

Coral Gables, United States · Post IPO Equity

The Org
helps you hire
great candidates

It takes less than ten minutes to set up your company page.
It’s free to use - try it out today.